News New heart attack data boost AZ’s Brilinta Andrew McConaghie AstraZeneca, Brilinta, cardiology, ESC2017, European Society of Cardiology 0 Comment A new sub-analysis of data from a phase 3 trial shows AstraZeneca’s Brilinta cuts the risk of cardiovascular death by 29% in high risk patients. Share X New heart attack data boost AZ’s Brilinta https://pharmaphorum.com/news/new-heart-attack-data-boost-azs-brilinta/